Quantcast

Global Chemotherapy Induced Anemia 2013: Worldwide Industry Latest Market Share, Growth, Size, Trends, Strategy and Forecast Research Report 2013

September 24, 2013

MarketResearchReports.Biz announces addition of new report “Chemotherapy Induced Anemia – Pipeline Review, H2 2013” to its database. Visit http://www.marketresearchreports.biz/analysis-details/chemotherapy-induced-anemia-pipeline-review-h2-2013.

Albany, NY (PRWEB) September 24, 2013

Chemotherapy Induced Anemia – Pipeline Review, H2 2013

Summary

Global Markets Directs, 'Chemotherapy Induced Anemia – Pipeline Review, H2 2013', provides an overview of the indications therapeutic pipeline. This report provides information on the therapeutic development for Chemotherapy Induced Anemia, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Chemotherapy Induced Anemia. Chemotherapy Induced Anemia – Pipeline Review, Half Year is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team.

To check out the complete table of contents, visit: http://www.marketresearchreports.biz/analysis-details/chemotherapy-induced-anemia-pipeline-review-h2-2013.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • A snapshot of the global therapeutic scenario for Chemotherapy Induced Anemia.
  • A review of the Chemotherapy Induced Anemia products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • Coverage of products based on various stages of development ranging from discovery till registration stages.
  • A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
  • Coverage of the Chemotherapy Induced Anemia pipeline on the basis of route of administration and molecule type.
  • Key discontinued pipeline projects.
  • Latest news and deals relating to the products.

Reasons to buy

  • Identify and understand important and diverse types of therapeutics under development for Chemotherapy Induced Anemia.
  • Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
  • Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
  • Devise corrective measures for pipeline projects by understanding Chemotherapy Induced Anemia pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175414

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 5

Introduction 6

Global Markets Direct Report Coverage 6

Chemotherapy Induced Anemia Overview 7

Therapeutics Development 8

An Overview of Pipeline Products for Chemotherapy Induced Anemia 8

Chemotherapy Induced Anemia Therapeutics under Development by Companies 10

Late Stage Products 11

Comparative Analysis 11

Mid Clinical Stage Products 12

Comparative Analysis 12

Early Clinical Stage Products 13

Comparative Analysis 13

Discovery and Pre-Clinical Stage Products 14

Comparative Analysis 14

Chemotherapy Induced Anemia Therapeutics – Products under Development by Companies 15

Companies Involved in Chemotherapy Induced Anemia Therapeutics Development 16

Eli Lilly and Company 16

Reliance Life Sciences Pvt. Ltd. 17

3SBio Inc. 18

ProMetic Life Sciences Inc. 19

Avesthagen Limited 20

Therapure Biopharma Inc. 21

Chemotherapy Induced Anemia – Therapeutics Assessment 22

Assessment by Monotherapy Products 22

Assessment by Route of Administration 23

Assessment by Molecule Type 25

Drug Profiles 27

NuPIAO – Drug Profile 27

Product Description 27

Mechanism of Action 27

R&D Progress 27

epoetin alfa – Drug Profile 28

Product Description 28

Mechanism of Action 28

R&D Progress 28

PBI-1402 – Drug Profile 30

Product Description 30

Mechanism of Action 30

R&D Progress 30

darbepoetin alfa biosimilar – Drug Profile 31

Product Description 31

Mechanism of Action 31

R&D Progress 31

LY-2787106 – Drug Profile 32

Product Description 32

Mechanism of Action 32

R&D Progress 32

PanCyte – Drug Profile 33

Product Description 33

Mechanism of Action 33

R&D Progress 33

epoetin – Drug Profile 35

Product Description 35

Mechanism of Action 35

R&D Progress 35

TBI-304 – Drug Profile 36

Product Description 36

Mechanism of Action 36

R&D Progress 36

TP-0413 – Drug Profile 37

Product Description 37

Mechanism of Action 37

R&D Progress 37

Drug For Chemotherapy Induced Anemia – Drug Profile 38

Product Description 38

Mechanism of Action 38

R&D Progress 38

Drug For Chemotherapy Induced Anemia – Drug Profile 39

Product Description 39

Mechanism of Action 39

R&D Progress 39

Chemotherapy Induced Anemia Therapeutics – Drug Profile Updates 40

Chemotherapy Induced Anemia Therapeutics – Discontinued Products 42

Chemotherapy Induced Anemia Therapeutics – Dormant Products 43

Chemotherapy Induced Anemia – Product Development Milestones 44

Featured News & Press Releases 44

Jan 03, 2013: Affymax And Takeda Pharma Announce Permanent J-Code For Omontys Injection Is In Effect 44

Apr 24, 2012: SBI Pharmaceuticals Announces Obtainment of Marketing Authorization of Products Containing 5-ALA from The Kingdom of Bahrain Ministry of Health 44

Jan 31, 2012: Kyowa Hakko Kirin Withdraws Domestic Application For Additional Chemotherapy-Induced Anemia Indication For NESP 45

Oct 28, 2011: ALA Study Results Presented at the 49th Annual Meeting of Japan Society of Clinical Oncology 45

Oct 05, 2011: ALA Study Results Presented at Japanese Cancer Association, 70th Annual Meeting 45

Jul 11, 2011: 3SBio Receives SFDA Approval For High-Dose EPIAO 46

Jun 02, 2011: Acceleron And Celgene Initiate Phase II/III Study Of ACE-011 To Treat Chemotherapy-Induced Anemia In Patients With Lung Cancer 47

Mar 18, 2011: Announcement of publication of ALA research in International Immunopharmacology 48

Sep 30, 2010: Safety study for subcutaneous epoetin alfa biosimilar Binocrit/Epoetin alfa Hexal/Abseamed suspended 48

Jun 06, 2010: Alder's ALD518 Antibody Therapeutic Reduces Disease Symptoms, Anemia In Phase IIa Clinical Trial In NSCLC Patients 48

Appendix 50

Methodology 50

Coverage 50

Secondary Research 50

Primary Research 50

Expert Panel Validation 50

To buy the copy of this report, visit: http://www.marketresearchreports.biz/analysis/175414.

Contact Us 51

Disclaimer 51 List of Tables

Number of Products Under Development for Chemotherapy Induced Anemia, H2 2013 8

Products under Development for Chemotherapy Induced Anemia – Comparative Analysis, H2 2013 9

Number of Products under Development by Companies, H2 2013 10

Comparative Analysis by Late Stage Development, H2 2013 11

Comparative Analysis by Mid Clinical Stage Development, H2 2013 12

Comparative Analysis by Early Clinical Stage Development, H2 2013 13

Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 14

Products under Development by Companies, H2 2013 15

Eli Lilly and Company, H2 2013 16

Reliance Life Sciences Pvt. Ltd., H2 2013 17

3SBio Inc., H2 2013 18

ProMetic Life Sciences Inc., H2 2013 19

Avesthagen Limited, H2 2013 20

Therapure Biopharma Inc., H2 2013 21

Assessment by Monotherapy Products, H2 2013 22

Assessment by Stage and Route of Administration, H2 2013 24

Assessment by Stage and Molecule Type, H2 2013 26

Chemotherapy Induced Anemia Therapeutics – Drug Profile Updates 40

Chemotherapy Induced Anemia Therapeutics – Discontinued Products 42

Chemotherapy Induced Anemia Therapeutics – Dormant Products 43 List of Figures

Number of Products under Development for Chemotherapy Induced Anemia, H2 2013 8

Products under Development for Chemotherapy Induced Anemia – Comparative Analysis, H2 2013 9

Products under Development by Companies, H2 2013 10

Late Stage Products, H2 2013 11

Mid Clinical Stage Products, H2 2013 12

Early Clinical Stage Products, H2 2013 13

Discovery and Pre-Clinical Stage Products, H2 2013 14

Assessment by Monotherapy Products, H2 2013 22

Assessment by Route of Administration, H2 2013 23

Assessment by Stage and Route of Administration, H2 2013 24

Assessment by Molecule Type, H2 2013 25

Assessment by Stage and Molecule Type, H2 2013 26

Latest Reports:

China Waste Heat Utilization Equipment Industry Report, 2013-2015: http://www.marketresearchreports.biz/analysis-details/china-waste-heat-utilization-equipment-industry-report-2013-2015

China has rich waste heat resources. Especially in steel, nonferrous, chemical, cement, building materials, oil & petrochemical, light industry, coal and other sectors, waste heat resources approximately occupy 17%-67% of the total fuel consumption, of which, recyclable waste heat resource roughly stand up 60% of the total waste heat resources. At present, China’s waste heat utilization ratio is rather low, with the figure in large steel enterprises being 30%-50%. But the waste heat utilization in other sectors is even lower. Thus, China is expected to see a huge potential to improve its waste heat utilization.

By temperature of waste heat, the waste heat utilization equipments fall into two categories: the first comes to waste heat boiler which uses medium-and high-temperature waste heat; the second refers to lithium bromide refrigerator (heat pump) and screw expander, both of which use low-temperature waste heat. Of these, waste heat boiler occupies a lion’s share in waste heat utilization equipments. In 2012, the output of waste heat boiler approximated 812 sets, totaling 39,788 steam tons.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175307

Technology Trends in Lubricants (Mineral, Synthetic, and Bio-based) Market for Turbine Oil, Compressor Oil, Gear Oil, Hydraulic Oil, Bearing Oil and Heat Transfer Fluid Lubricant Applications – Global Industry Analysis, Size, Share, Growth, Trends and Forecast, 2012 – 2018: http://www.marketresearchreports.biz/analysis-details/technology-trends-in-lubricants-mineral-synthetic-and-bio-based-market-for-turbine-oil-compressor-oil-gear-oil-hydraulic-oil-bearing-oil-and-heat-transfer-fluid-lubricant-applications-global-industry-analysis-size-share-growth-trends-a

Synthetic and bio-based lubricants are the major emerging lubricant products. This study highlights and explores key technology trends of synthetic, bio-based and mineral lubricants across a wide range of applications including turbine oil, compressor oil, gear oil, hydraulic oil, heat transfer fluids and bearing oil lubricants. Some of the major qualities that differentiate between lubricants include viscosity index, water separation characteristics, thermal and oxidation stability, low volatility and low carbon formation, and anticorrosion.

This market research report, analyzes the global consumption for lubricants, estimating and forecasting the market from the consumption point of view. The lubricants market has been segmented on the basis of products, applications and geography in order to provide a holistic picture of the market. Market data for all product segments has been provided on a regional level for the period 2011 to 2018. Technology trends have been provided for applications to give an overall idea about the latest happenings in the market. A comprehensive competitive landscape including company market share analysis has also been provided in this analysis.

Click Here To Download Detail Report: http://www.marketresearchreports.biz/sample/sample/175269

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are specially designed to save time and money for our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

Tel: +1-518-618-1030

USA – Canada Toll Free: 866-997-4948

Website: http://www.marketresearchreports.biz/

Blog: http://mresearchreports.blogspot.com

For the original version on PRWeb visit: http://www.prweb.com/releases/2013/9/prweb11154906.htm


Source: prweb



comments powered by Disqus